ストックスクリーナーアプリを入手
8.95
7.73%
-0.75
アフターアワーズ：
8.95
前日終値:
$9.70
開ける：
$9.78
24時間の取引高:
34,441
Relative Volume:
7.87
時価総額：
$5.04M
収益：
$7.10M
当期純損益:
$-39.43M
株価収益率:
-9.5213
EPS:
-0.94
ネットキャッシュフロー:
$-46.50M
1週間 パフォーマンス:
+5.29%
1か月 パフォーマンス:
-98.35%
6か月 パフォーマンス:
-86.69%
1年 パフォーマンス:
-90.34%
1日の値動き範囲:
$8.49
$9.78
1週間の範囲:
$7.26
$10.20
52週間の値動き範囲:
$7.26
$543.38
Spruce Biosciences Inc Stock (SPRB) Company Profile
名前
Spruce Biosciences Inc
セクター
電話
(415) 655-4168
住所
611 GATEWAY BOULEVARD, SUITE 740, SOUTH SAN FRANCISCO
SPRB を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SPRB
Spruce Biosciences Inc
|
8.95 | 5.46M | 7.10M | -39.43M | -46.50M | -0.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.64 | 101.35B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.00 | 58.66B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
562.27 | 59.43B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
737.56 | 44.01B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
340.70 | 36.56B | 3.81B | -644.79M | -669.77M | -6.24 |
Spruce Biosciences Inc Stock (SPRB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-11 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-12-11 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2024-03-14 | ダウングレード | Guggenheim | Buy → Neutral |
| 2024-03-14 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2024-03-14 | ダウングレード | Ladenburg Thalmann | Buy → Neutral |
| 2024-03-14 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2024-03-14 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-21 | 開始されました | Guggenheim | Buy |
| 2021-12-17 | 開始されました | Oppenheimer | Outperform |
| 2021-12-10 | 開始されました | The Benchmark Company | Speculative Buy |
| 2021-11-16 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2021-07-19 | 開始されました | H.C. Wainwright | Buy |
| 2021-04-26 | 再開されました | Credit Suisse | Outperform |
| 2020-11-03 | 開始されました | Cowen | Outperform |
| 2020-11-03 | 開始されました | Credit Suisse | Outperform |
| 2020-11-03 | 開始されました | RBC Capital Mkts | Outperform |
| 2020-11-03 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Spruce Biosciences Inc (SPRB) 最新ニュース
Critical Contrast: Spruce Biosciences (SPRBD) vs. Its Rivals - Defense World
Reviewing Spruce Biosciences (SPRBD) & Its Rivals - Defense World
Spruce Biosciences, Inc.(NasdaqCM: SPRB) added to NASDAQ Composite Index - MarketScreener
Spruce Biosciences Resumes Trading on the Nasdaq Capital Market - BioSpace
Spruce Biosciences resumes Nasdaq trading today - Investing.com
Spruce Biosciences Announces Integrated Long-Term Clinical Data of Tralesinidase Alfa Enzyme Replacement Therapy Demonstrating Profound and Durable Efficacy and Safety in Patients with Sanfilippo Syndrome Type B - Investing News Network
One new option listing and two option delistings on September 5th - TipRanks
Head to Head Contrast: Spruce Biosciences (SPRBD) versus Its Peers - Defense World
Spruce Biosciences (SPRBD) & The Competition Critical Review - Defense World
Spruce Biosciences (SPRBD) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - sharewise.com
Spruce Biosciences (NASDAQ:SPRB) Trading Down 1.6% – What’s Next? - Defense World
Contrasting Spruce Biosciences (SPRBD) and The Competition - Defense World
Financial Analysis: MusclePharm (OTCMKTS:MSLP) & Spruce Biosciences (NASDAQ:SPRB) - Defense World
Research Analysts Set Expectations for OTC:SPRBD Q1 Earnings - Defense World
Spruce Biosciences Reports Promising Clinical Advances - TipRanks
Cautious Optimism for Spruce Biosciences Amid Promising Data and Financial Uncertainty - TipRanks
Head to Head Survey: Zomedica (OTC:ZOMDF) vs. Spruce Biosciences (NASDAQ:SPRB) - Defense World
Spruce Biosciences Announces Integrated Long-Term Clinical Data of Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) Demonstrating Profound and Durable Efficacy and Safety in Patients with Sanfilippo Syndrome Type B (MPS IIIB) - BioSpace
Spruce Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates - BioSpace
Spruce Biosciences reports positive long-term data for MPS IIIB therapy - Investing.com Nigeria
Spruce Biosciences Announces Integrated Long-Term Clinical Data of Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) Demonstrating Profound and Durable Efficacy and Safety in Patients with Sanfil - StreetInsider
Spruce Biosciences (SPRB) Expected to Announce Earnings on Monday - Defense World
Head to Head Analysis: Gemini Therapeutics (NASDAQ:GMTX) and Spruce Biosciences (NASDAQ:SPRB) - Defense World
Curis (CRIS) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Press Release: Spruce Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates - 富途牛牛
Spruce Biosciences (NASDAQ:SPRB) Shares to Reverse Split on Monday, August 4th - Defense World
Spruce Biosciences Announces Reverse Stock Split Plan - The Globe and Mail
Spruce Biosciences to enact 1-for-75 reverse stock split - MSN
Spruce Biosciences to implement 1-for-75 reverse stock split - Investing.com
Spruce Biosciences Announces Reverse Stock Split - Business Wire
HMNC Brain Health and Spruce Biosciences Announce First Patient Dosed in Phase 2 TAMARIND Trial For Major Depressive Disorder - The Manila Times
Spruce Biosciences (SPRB) Advances in Phase 2 Depression Treatme - GuruFocus
Spruce Biosciences (NASDAQ:SPRB) Trading Up 5.7% – Here’s What Happened - Defense World
Layoff Tracker: Following Challenges With DMD Therapy, Sarepta Will Cut 500 Employees - BioSpace
New weight reduction data for Crenessity presented by Neurocrine - The Pharma Letter
Ultragenyx hit again, this time with a CRL in rare disease - BioWorld MedTech
Spruce Biosciences (SPRB) Gains Investor Attention with Significant Interest Surge | SPRB Stock News - GuruFocus
Spruce Biosciences gets conditional approval to resume trading on Nasdaq Capital Market - MSN
Spruce Biosciences (NASDAQ:SPRB) versus Pharmaxis (OTCMKTS:PXSLY) Head-To-Head Analysis - Defense World
Congenital Adrenal Hyperplasia Treatment Market Outlook Influenced by Gene Therapy Innovations 2025 - openPR.com
SPRB ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Spruce Biosciences, Inc. - ACCESS Newswire
BriaCell Therapeutics (OTCMKTS:BCTXF) vs. Spruce Biosciences (NASDAQ:SPRB) Head-To-Head Survey - Defense World
Congenital Adrenal Hyperplasia Pipeline Insight, 2025: - openPR.com
Spruce Biosciences (SPRB) Secures Nasdaq Approval for Relisting - GuruFocus
Spruce Biosciences Announces Conditional Nasdaq Approval to Resu - GuruFocus
# Spruce Biosciences to resume Nasdaq trading pending stock split approval By Investing.com - Investing.com South Africa
Spruce Biosciences Inc (SPRB) 財務データ
収益
当期純利益
現金流量
EPS
2.36%
1.10%
大文字化:
|
ボリューム (24 時間):